Normax Biomed Ltd (Normax) is based in Cork, Ireland, and London, England. Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative Social Impact on Infectious Disease and Pandemic Preparedness. Normax plans to drive down the cost of mRNA Vaccines to save more lives and to deliver sustainable returns for impact investors. Normax plans to deliver safe and effective mRNA vaccines at large scale for about $4 dollars per dose. Normax mRNA vaccine products in development include: (1) mRNA Vax Factory, (2) Universal Coronavirus mRNA Vaccine, (3) Tuberculosis mRNA Vaccine, (4) HIV mRNA Vaccine, (5) Malaria mRNA Vaccine, and (6) Disease-X mRNA Vaccine (e.g. within 100 days). Normax mission is to deliver competitive financial performance with transformative social impact. NOT AN OFFER TO INVEST.

Peter A. Jensen, Author at id.normaxbiomed.com

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the London Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the London Stock Exchange and the Swiss Stock Exchange (SIX).

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.

About Peter A. Jensen

NEWS. ECDC. 9 Jan 2023. Update on SARS-CoV-2 variants: ECDC assessment of the XBB.1.5 sub-lineage

GROUND TRUTHS. REPORT. DR ERIC TOPOL. JAN 12. The bivalent vaccine booster outperforms. A review of the cumulative body of evidence.

NEWS. NATURE. 09 January 2023. Coronavirus variant XBB.1.5 rises in the United States — is it a global threat?

NEWS. REUTERS. Moderna Considers Price of $110-$130 for Covid-19 Vaccine – WSJ – 09 JAN 2023

INTERVIEW. Gianluca Vialli: ‘Now I realise that whenever I want to cry, I cry’ – The Guardian. Gianluca Vialli Died of Pancreatic Cancer 8th January 2023.

WHO REPORT. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2023, 5 January 2023

XBB.1.5. “MOST TRANSMISSABLE SUBVARIANT” – WHO. 04 JAN 2023

PHARMACEUTICAL MARKET DATA. Pfizer/BioNTech and Moderna Covid-19 mRNA Vaccines Leading Worldwide Drug Sales 2021/22

BIOSECURITY VIEWPOINT. Inevitable Emergence of New Variants of Concern. Ongoing SARS-CoV-2 Global Evolution, Exploding Now in China.

CDC COVID DATA TRACKER. Monitoring Variant Proportions: 9/18/2022 – 12/24/2022

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.

Normax Abstract